These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 36544755)

  • 21. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients.
    Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G
    Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
    Li B; Cui Y; Diehn M; Li R
    JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioinformatics analysis of differentially expressed miRNAs in non-small cell lung cancer.
    Yu H; Pang Z; Li G; Gu T
    J Clin Lab Anal; 2021 Feb; 35(2):e23588. PubMed ID: 32965722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
    Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
    Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients.
    Schlensog M; Magnus L; Heide T; Eschenbruch J; Steib F; Tator M; Kloten V; Rose M; Noetzel E; Gaisa NT; Knüchel R; Dahl E
    Epigenetics; 2018; 13(3):214-227. PubMed ID: 27623992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
    Hou G; Lu Z; Bi Y; Deng J; Yang X
    Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Li Y; Zheng P; Zhan X
    Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma.
    Zhang W; Li Y; Lyu J; Shi F; Kong Y; Sheng C; Wang S; Wang Q
    Cancer Sci; 2022 Mar; 113(3):891-903. PubMed ID: 34967077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression Pattern and Prognostic Analysis of Branched-Chain Amino Acid Catabolism-Related Genes in Non-Small Cell Lung Cancer.
    Yao X; Deng Y; Zhou J; Jiang L; Song Y
    Front Biosci (Landmark Ed); 2023 Jun; 28(6):107. PubMed ID: 37395022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
    Yang Y; Wang M; Liu B
    J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma.
    Li X; Dai Z; Wu X; Zhang N; Zhang H; Wang Z; Zhang X; Liang X; Luo P; Zhang J; Liu Z; Zhou Y; Cheng Q; Chang R
    Front Immunol; 2022; 13():749241. PubMed ID: 35529878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidermal Growth Factor Receptor Mutations in Resectable Non-Small Cell Lung Cancer Patients and their Potential Role in the Immune Landscape.
    Xia W; Mao W; Chen R; Lu R; Liu F; He Y; Wang S; Li X; Zheng M
    Med Sci Monit; 2019 Nov; 25():8764-8776. PubMed ID: 31746315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blood FOLR3 methylation dysregulations and heterogeneity in non-small lung cancer highlight its strong associations with lung squamous carcinoma.
    Qu Y; Zhang X; Qiao R; Di F; Song Y; Wang J; Ji L; Zhang J; Gu W; Fang Y; Han B; Yang R; Dai L; Ouyang S
    Respir Res; 2024 Jan; 25(1):59. PubMed ID: 38273401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.
    Feng Z; Yin Y; Liu B; Zheng Y; Shi D; Zhang H; Qin J
    Cancer Control; 2022; 29():10732748221076682. PubMed ID: 35212236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing.
    Wang C; Yu Q; Song T; Wang Z; Song L; Yang Y; Shao J; Li J; Ni Y; Chao N; Zhang L; Li W
    Signal Transduct Target Ther; 2022 Aug; 7(1):289. PubMed ID: 36008393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LINC00628 is differentially expressed between lung adenocarcinoma and squamous cell carcinoma and is associated with the prognosis of NSCLC.
    Liu T; Xu S; Liu X
    Oncol Lett; 2022 Feb; 23(2):55. PubMed ID: 34992687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carbonic Anhydrase 4 Serves as A Novel Prognostic Biomarker and Therapeutic Target for Non-Small Cell Lung Cancer: A Study Based on TCGA Samples.
    Xu B; Lou Y; Xu X; Li X; Tian X; Yu Z; Chen X
    Comb Chem High Throughput Screen; 2023; 26(14):2527-2540. PubMed ID: 36944625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ferroptosis-Related Genes Are Potential Therapeutic Targets and the Model of These Genes Influences Overall Survival of NSCLC Patients.
    Zhang N; Wu Y; Wu Y; Wang L; Chen J; Wang X; Chard Dunmall LS; Cheng Z; Wang Y
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
    Meng F; Zhang L; Ren Y; Ma Q
    J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of lung adenocarcinoma subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genes.
    Hua L; Wu J; Ge J; Li X; You B; Wang W; Hu B
    Front Cell Dev Biol; 2023; 11():1060086. PubMed ID: 37234773
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.